Nektar CMO Mary Tagliaferri resigns; Brian Kotzin named interim CMO

NEKTAR THERAPEUTICS

Mary Tagliaferri resigned as SVP and CMO effective Feb 4, 2025, for personal reasons; no disagreement with company.
Brian Kotzin, MD, appointed interim CMO; he previously served as strategic advisor for rezpegaldesleukin program since April 2023.
Kotzin has over 40 years immunology experience; was VP at Amgen and held academic positions; will assist search for permanent CMO.
Kotzin currently serves on boards of Argenx SE, Biora Therapeutics, and Genascence Corporation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.